Rosana Kapeller, Rome Therapeutics CEO

Rome Ther­a­peu­tics ad­vances dark genome drug af­ter com­plet­ing $72M Se­ries B ex­ten­sion backed by Big Phar­ma

Dark genome-fo­cused biotech Rome Ther­a­peu­tics has com­plet­ed an over­sub­scribed $72 mil­lion Se­ries B ex­ten­sion sup­port­ed by new Big Phar­ma back­ers, with an eye to ad­vanc­ing its lead an­ti-in­flam­ma­to­ry pro­gram in­to clin­i­cal tri­als.

The Boston-based com­pa­ny raised $77 mil­lion in its orig­i­nal Se­ries B round in Sep­tem­ber 2021 and has now com­plet­ed the ex­ten­sion phase sup­port­ed by in­vestors, in­clud­ing the ven­ture arms of Sanofi, Bris­tol My­ers Squibb and John­son & John­son, bring­ing the to­tal to $149 mil­lion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.